# Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Canonical: https://abierto.us/opportunities/ht940226q9101

- Solicitation number: HT9402-26-Q-9101
- Notice type: Solicitation
- Status: Closed. Deadline was January 16, 2026 at 1:00 PM EST
- Department: Department of Defense
- Agency: Defense Health Agency (Dha)
- Contracting office: Defense Health Agency (HT9402)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: San Antonio, Texas
- County: Bexar County (FIPS 48029). https://abierto.us/counties/bexar-county-tx-48029
- City: San Antonio. https://abierto.us/cities/san-antonio-tx-4865000
- First posted: November 18, 2025
- Last posted: January 8, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/276d0a5c639840cfbb8ed6f150086132/view

## Description

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision.

This process is described in the attached RFQ. a. Oncological Agents – Myelofibrosis Inrebic Jakafi Ojjaara Vonjo he RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9101. Pre-quotation teleconference is on November 20, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.

## Publications

- November 18, 2025: Solicitation, due January 16, 2026 at 1:00 PM EST. Notice f14c9c8aff0f480c9a04e16bad546109. https://sam.gov/workspace/contract/opp/f14c9c8aff0f480c9a04e16bad546109/view
- December 4, 2025: Solicitation, due January 16, 2026 at 1:00 PM EST. Notice 93700573373f4c5ba89750ce9466b1ca. https://sam.gov/workspace/contract/opp/93700573373f4c5ba89750ce9466b1ca/view
- January 8, 2026: Solicitation, due January 16, 2026 at 1:00 PM EST. Notice 276d0a5c639840cfbb8ed6f150086132. https://sam.gov/workspace/contract/opp/276d0a5c639840cfbb8ed6f150086132/view

## Points of contact

- Tracy Banks, tracy.e.banks2.civ@health.mil
- Stephanie Erpelding, stephanie.j.erpelding.civ@health.mil

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/ht940226q9101.